Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50

EMCCD camera and 3D imaging

By Drug Discovery Trends Editor | June 22, 2010

With the help of a highly sensitive Andor iXon+ EMCCD camera, US researchers have developed a super-resolution, 3D imaging technique that can resolve single fluorescent molecules with greater than 10 times more precision than conventional optical microscopy. By being able to locate molecules to within 12 – 20nm in all three axes, the researchers hope to be able to observe interactions between nanometer-scale intracellular structures previously too small to see.

This major advance in 3D super-resolution imaging has been achieved by combining two concepts: super-resolution imaging by sparse photoactivation of single-molecule labels (PALM, STORM, F-PALM), coupled with a double-helix point spread function (DH-PSF) to provide accurate z-position information.

Prof. Rafael Piestun at the University of Colorado and his students developed a PSF with two rotating lobes where the angle of rotation depends on the axial position of the emitting molecule. This means the PSF appears as a double helix along the z-axis of the microscope, lending it the distinctive name of ‘Double Helix PSF’.  Prof. W. E. Moerner at Stanford University and his team realized that the DH-PSF could be used for super-resolution imaging with single molecules.  With the DH-PSF, a single emitting fluorescent molecule emits a pattern corresponding to a standard PSF, but the image this creates is convolved with the DH-PSF using Fourier optics and a reflective mask outside the microscope. At the detector, the image from a single molecule appears as two spots, rather than one. The orientation of the pair can be used to decode the z-location of a molecule, which combined with the 2D localization data, enables the 3D position to be accurately defined. Furthermore, the DH-PSF approach has been shown to extend the depth of field to ~ 2 µm in the specimen, approximately twice that which has been achieved in other 3D super-resolution techniques.

Commenting on the role played by the Andor iXon+ EMCCD camera in this breakthrough, Prof. Moerner, said, “As the localization precision of our super-resolution technique improves at a rate of one over the square root of the number of photons detected, it was essential to use a camera that allowed us to detect every possible photon from each single molecule.  Put simply, the more photons we detected, the greater the x, y, and z precision1.  However, the speed of imaging is also important. Since we need to acquire multiple images for each reconstruction, it is always best to record the images as fast as possible.”

The DH-PSF’s usefulness was recently validated in a 3D localisation experiment involving imaging of a single molecule of the new fluorogen, DCDHF-V-PF4 azide2. This photoactivatable molecule was chosen as it emits a large number of photons before it bleaches, and is easily excited.  By operating the EMCCD camera at a constant EM gain setting of x250, to eliminate the read noise detection limit, it was possible to acquire many images of the single photoactivated molecule. From these images, the x-y-z position of the fluorophore could be determined with 12-20nm precision, depending on the dimension of interest.

Prof Moerner and his team have called this new technique single molecule Double Helix Photoactivated Localization Microscopy (DH-PALM), and are confident that it will provide far more useful information than is the case for other approaches to extracting 3D positional information. “We expect that the DH-PSF optics will become a regular attachment on advanced microscopes, either for super-resolution 3D imaging of structures, or for 3D super-resolution tracking of individually labelled bio-molecules in cells or other environments.”

Notes:

1) Thompson, M.A.; Lew, M.D.;Bedierrostami, M.; Moerner, W. E.; Nano Lett. 2010, 10,211-218

2) Pavani, S.R.p; Thompson, M.A.;Biteen, J.A.; Lord, S.J.; Liu, N;Twieg, R.J.; Piestun, R.; Moerner, W.E. Proc. Natl. Acad. Sci. U.S.A. 2009, 9, 2995-2999

 


Filed Under: Drug Discovery

 

Related Articles Read More >

Roche in Drug Discovery & Development Pharma 50
Roche’s bispecific antibody Lunsumio wins priority review from FDA for non-Hodgkin lymphoma
Tiffany Hurd
CB Therapeutics biz dev lead sees upside for psychedelics in mental health and beyond
Pharmacovigilance
A new era of pharmacovigilance: Worldwide master key for drug safety monitoring
Takeda Pharmaceutical in the Drug Discovery & Development Pharma 50
Takeda’s Takhzyro fares well in pediatric hereditary angioedema study

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MASSDEVICE
  • DEVICETALKS
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • MEDTECH 100
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50